David E.I. Pyott, CBE, MD (Hon.)
Former Chairman of the Board and Chief Executive Officer of Allergan, Inc. 1998-2015
During his 17 year tenure, Allergan was transformed from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014 with most of the increase stemming from organic growth. Allergan’s market capitalization increased from $2.3 billion in 1998 to $72 billion when Allergan was acquired by Actavis in 2015. Dr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4). He has lived in 10 countries and worked in 7 countries ranging from the U.S. to Europe and Asia.
In 2006, Dr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree and an Honorary Degree in Medicine from the University of Edinburgh and a Master of Business Administration degree from the London Business School. Dr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., a member of the Supervisory Board of Royal Philips in the Netherlands and Chairman of Bioniz Therapeutics. He is a Governor of London Business School, President of the International Council of Ophthalmology Foundation and is also involved on the Boards of many of the other US and international eyecare charities.